Neovasc (NSDQ:NVCN) said today that its Reducer device designed for treating refractory angina was used in its first procedure in the US. The Reducer system is designed to alter blood flow in the heart’s circulatory system to increase perfusion of oxygenated blood to ischemic areas of heart muscle, and can be placed in a minimally invasive transvenous […]
EuroPCR Roundup: Biotronik touts two-year study comparing drug-eluting stents
Biotronik yesterday presented two-year data from a trial comparing Boston Scientific‘s (NYSE:BSX) Synergy biodegradable polymer everolimus-eluting stent, Biotronik’s Orsiro sirolimus-eluting stent and Medtronic‘s (NYSE:MDT) Resolute Integrity zotarolimus-eluting stent. Results from the 3,514-patient trial showed no significant difference between the various stents regarding the rate of target vessel failure after two years. But analyses of one-year data found differences between the rates of […]
8 companies commercializing transcatheter mitral valve replacements
Transcatheter mitral valve replacement is a new frontier in the cardio device field, with big legacy medical device companies including Edwards Lifesciences, Medtronic and Abbott spending hundreds of millions of dollars on companies in the space. Much different from transcatheter aortic valve replacement (TAVR), transcatheter mitral valve replacement (TMVR) has been mostly experimental. TMVR is used […]
Neovasc continues pursuit of 1-for-100 reverse stock split
Neovasc (NSDQ:NVCN) said today that it will proceed with plans for a reverse stock split with a ratio of up to 1-for-100, with board members and management urging shareholders to vote for the proposal at an upcoming special meeting. The Vancouver-based company will vote on the proposition on June 4, according to a recently posted SEC […]
Neovasc shares down on Q1 miss, plans 1-for-100 reverse split
Shares in Neovasc (NSDQ:NVCN) have fallen today after the medical device maker missed Wall Street expectations and posted growing losses in its first quarter earnings release, alongside plans for a 1-for-100 reverse split. The Vancouver-based company posted losses of $55.5 million, or 38¢ per share, on sales of $339,922 for the three months ended March 31, […]
Neovasc raises $7m in warrants offering
Neovasc (NSDQ:NVCN) said today that it raised more than $7 million in a warrants offering. Vancouver-based Neovasc said the offering, of nearly 4.9 million Series C warrants at an exercise price of $1.46 apiece, resulted in gross proceeds of $7.1 million. “This receipt into treasury is significant. We believe it is sufficient to substantially fund the […]
NeoVasc shares tumble on 2017 earnings release, sales slide nearly 50%
Shares in Neovasc (NSDQ:NVCN) have fallen nearly 50% today after the structural heart device maker posted shrinking sales in its 2017 earnings release and updated on progress with its investigational Tiara mitral valve replacement. The Vancouver-based company posted losses of $22.9 million, or 28¢ per share, on sales of $5.4 million for the full 2017 year, […]
Neovasc wins German reimbursement for Reducer system
Neovasc (NSDQ:NVCN) said today that it won reimbursement coverage from the German Institute for the Hospital Renumberation System for its Reducer device designed to treat refractory angina. The Reducer system is designed to alter blood flow in the heart’s circulatory system to increase perfusion of oxygenated blood to ischemic areas of heart muscle, and can be placed […]
Neovasc taps former Boston Scientific CRM vet Colen for CEO | Personnel Moves January 22, 2018
Neovasc (NSDQ:NVCN) said today it tapped former Boston Scientific (NYSE:BSX) cardiac rhythm management lead Fred Colen as its new chief executive officer, with former CEO Alexei Marko staying on as an advisor and member of the company’s board of directors. The move comes as part of a company-wide strategy looking to support commercialization efforts for its Reducer […]
Neovasc ticks up on Tiara valve update
Neovasc (NSDQ:NVCN) today reported low leak rates in the clinical program for its Tiara mitral valve replacement and a 30-day all-cause mortality rate of nearly 10%. Vancouver-based Neovasc said 47 patients have been implanted with the Tiara transcatheter mitral valve replacement using a roughly 20-min. procedure, with 42 reaching the 30-day mark. The all-cause mortality rate […]
Neovasc raises $65m to cover damages in CardiAQ case
Neovasc (NSDQ:NVCN) said today it closed an offering of approximately $37.5 million and a private placement of approximately $27.8 million to cover the roughly $42 million balance of damages and interest in a litigation with Edwards Lifesciences (NYSE:EW) subsidiary CardiAQ Valve. In its offering, Neovasc offered approximately 6.6 million Series A units and 19.1 million Series B units at a […]
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 7
- Next Page »
MassDevice Network
@MassDevice
LinkedIn
YouTube